European Journal of Biomedical and Pharmaceutical Sciences

A REVIEW ON RHEUMATOID ARTHRITIS

Gaware Rutuja J., Gaikwad V. M., Nagoba Shivappa N.*, Wadulkar R. D. and Wattmwar Pragati

ABSTRACT

Rheumatoid arthritis (RA) is a chronic inflammatory and systemic auto immune disease affecting people predominantly between the ages of 20-50 years with unpredictable course. About 1% of the world's population is afflicted by rheumatoid arthritis and is two - three times more common in women than men. Rheumatoid Arthritis occurs in about 5% of 1000 people and can lead to severe joint damage and disability. There are different types of arthritis. The rheumatoid arthritis due to the presence of pro-inflammatory markers, cytokines and leukotrines. The primary inflammatory markers are IL-1, TNF-α, IL-6, IL-15, IL-16, IL-17, IL-18, IFN-γ, and granulocyte macrophage-colony stimulating factor, chemokines such as IL-8, macrophage inflammatory protein-1 and monocyte chemo attractant protein-1. TNF-α blockade, IL-1 blockade, B cells therapy, IL-6 blockade and Angiogenesis blockade, these are therapeutic target for its treatment. Besides early diagnosis, these advances include early institution of disease modifying therapy with a goal of “treat to target”, frequent assessments of disease activity to control, consideration for and introduction of alternative or additive diseases modifying therapeutic agents in case of inadequate or persistent disease activity.

Keywords: Auto immune disease, Anti-arthritic potential, cytokines, Rheumatoid arthritis.